Janssen terminates izencitinib deal with Theravance Biopharma
In an8-K filing, Theravance Biopharma(NASDAQ:TBPH)said that Janssen Biotech, a Johnson & Johnson(NYS
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email:uservice@ttm.financial